Title

Efficacy and Safety of Rezum System Water Vapor Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Publication Date

2015

Journal Title

Urology

Abstract

OBJECTIVES: To assess 1 year efficacy and safety data from pilot trials of the Rezum System water vapor to treat lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). METHODS: A total of 65 men with symptoms of moderate to severe BPH were enrolled in pilot studies at centers in the Dominican Republic, the Czech Republic, and Sweden. Each patient was treated with transurethral delivery of sterile water vapor (steam). International Prostate Symptom Score (IPSS), peak urinary flow (Qmax), quality of life (QoL), post void residual (PVR), International Index of Erectile Function (IIEF) and prostate-specific antigen (PSA) were evaluated at 1 week and 1, 3, 6 and 12 months post-treatment. Safety was also assessed. RESULTS: Statistically significant clinical improvements at 1, 3, 6, and 12 months were reported for IPSS (decreased by 6.8, 13.4 13.1, and 12.5 points, respectively) and Qmax (increased by 2.0, 4.7, 4.3, and 4.6 ml/sec, respectively). At 12 months, these results equated to a 56% improvement in IPSS (P

Volume Number

86

Issue Number

5

Pages

1042-7

Document Type

Article

EPub Date

2015/07/29

Status

Northwell Researcher

Facility

Northwell Health

Primary Department

Urology

PMID

26216644

DOI

10.1016/j.urology.2015.05.046